Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trialYoshimasa Shiraishi, Isamu Okamoto, Shogo Nomura et al.|The Lancet Respiratory Medicine|2024Cited by 43
Gender Difference in Treatment Outcomes in Patients with Stage III Non-small Cell Lung Cancer Receiving Concurrent ChemoradiotherapyIkuo Sekine, T Tamura, Minako Sumi et al.|Japanese Journal of Clinical Oncology|2009Cited by 14
TRUST-II: A global phase II study for taletrectinib in <i>ROS1</i> fusion–positive lung cancer and other solid tumors.Misako Nagasaka, Yuichiro Ohe, Shunichi Sugawara et al.|Journal of Clinical Oncology|2022Cited by 4
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trialsD. Ross Camidge, Sanjay Popat, Shunichi Sugawara et al.|Lung Cancer|2025Cited by 3